Готові списки джерел за темами / Immunization Victoria

Добірка наукової літератури з теми "Immunization Victoria"

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Статті в журналах
Дисертації
Частини книг

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Immunization Victoria".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Immunization Victoria"

Levandowski, Roland A., Helen L. Regnery, Eldridge Staton, B. Gail Burgess, Michael S. Williams, and Jessie R. Groothuis. "Antibody Responses to Influenza B Viruses in Immunologically Unprimed Children." Pediatrics 88, no. 5 (November 1, 1991): 1031–36. http://dx.doi.org/10.1542/peds.88.5.1031.

Повний текст джерела

Анотація:

The cocirculation in several parts of the world of influenza viruses B/Yamagata/16/88 and B/Victoria/2/87, which are genetically and antigenically divergent, has prompted the question of whether immunization with one viral antigen is sufficient for protection against both strains. Twenty-three high-risk infants and young children were immunized with a commercial trivalent influenza vaccine containing the antigens of influenza virus B/Yamagata/16/88. When antibodies against influenza viruses B/Yamagata/16/88 and B/Victoria/2/87 were determined, increases developed uniformly to both in the sera of primed children previously exposed to influenza virus B/Victoria/2/87 by immunization or infection. Antibodies against B/Yamagata/16/88 developed in the sera of unprimed children with titers similar to those of the primed children. However, antibodies to B/ Victoria/2/87 were not detected in the sera of the unprimed children. These data suggest that children with out appropriate immunologic priming may not be protected against an infection with a B/Victoria/2/87 strain after vaccination with a B/Yamagata/16/88 strain. Immunization with more than one influenza B virus strain may be desirable in some high-risk pediatric patients if divergent influenza B viruses circulate.

Стилі APA, Harvard, Vancouver, ISO та ін.

Desheva, Yu A., T. A. Smolonogina, E. M. Doroshenko, and L. G. Rudenko. "Development of the quadrivalent live attenuated influenza vaccine including two influenza B lineages – Victoria and Yamagata." Problems of Virology 61, no. 1 (February 28, 2016): 16–20. http://dx.doi.org/10.18821/0507-4088-2016-61-1-16-20.

Повний текст джерела

Анотація:

This work is devoted to the research of the live attenuated influenza vaccine (LAIV) comprising two reassortant B/USSR/60/69-based vaccine influenza viruses Victoria and Yamagata. the intranasal immunization of the CBA mice with both victoria and yamagata strains induced 100% lung protection against the subsequent infection with the wild-type influenza B viruses of any antigen lineage. the quadrivalent LAIV (qLAIV) comprising both reassortant influenza B viruses Victoria and Yamagata were safe and areactogenic in adult volunteers. Following qLAIV administration the immune response was achieved to both Victoria and Yamagata lineages.

Стилі APA, Harvard, Vancouver, ISO та ін.

Costa, Jaline Cabral da, Marilda Mendonça Siqueira, David Brown, Jonathan Oliveira Lopes, Braulia Caetano da Costa, Eric Lopes Gama, and Maria de Lourdes Aguiar-Oliveira. "Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B Victoria and Yamagata Infections in Brazil over the Decade 2010–2020: A Statistical and Phylogeny–Trait Analyses." Viruses 14, no. 7 (July 5, 2022): 1477. http://dx.doi.org/10.3390/v14071477.

Повний текст джерела

Анотація:

Worldwide, infections by influenza viruses are considered a major public health challenge. In this study, influenza B vaccine mismatches and clinical aspects of Victoria and Yamagata infections in Brazil were assessed. Clinical samples were collected from patients suspected of influenza infection. In addition, sociodemographic, clinical, and epidemiological information were collected by the epidemiological surveillance teams. Influenza B lineages were determined by real-time RT-PCR and/or Sanger sequencing. In addition, putative phylogeny–trait associations were assessed by using the BaTS program after phylogenetic reconstruction by a Bayesian Markov Chain Monte Carlo method (BEAST software package). Over 2010–2020, B/Victoria and B/Yamagata-like lineages co-circulated in almost all seasonal epidemics, with B/Victoria predominance in most years. Vaccine mismatches between circulating viruses and the trivalent vaccine strains occurred in five of the eleven seasons (45.5%). No significant differences were identified in clinical presentation or disease severity caused by both strains, but subjects infected by B/Victoria-like viruses were significantly younger than their B/Yamagata-like counterparts (16.7 vs. 31.4 years, p < 0.001). This study contributes to a better understanding of the circulation patterns and clinical outcomes of B/Victoria- and B/Yamagata-like lineages in Brazil and advocate for the inclusion of a quadrivalent vaccine in the scope of the Brazilian National Immunization Program.

Стилі APA, Harvard, Vancouver, ISO та ін.

Baxter, C. M., H. J. Clothier, and K. P. Perrett. "Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia." Human Vaccines & Immunotherapeutics 14, no. 8 (May 10, 2018): 2088–92. http://dx.doi.org/10.1080/21645515.2018.1460293.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Silcock, Rowena, Nigel W. Crawford, Gowri Selvaraj, Alissa McMinn, Margie Danchin, Teresa Lazzaro, and Kirsten P. Perrett. "Subcutaneous nodules following immunization in children; in Victoria, Australia from 2007 to 2016." Vaccine 38, no. 15 (March 2020): 3169–77. http://dx.doi.org/10.1016/j.vaccine.2019.12.066.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Cheng, Daryl R., Kirsten P. Perrett, Sharon Choo, Margie Danchin, Jim P. Buttery, and Nigel W. Crawford. "Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013." Vaccine 33, no. 13 (March 2015): 1602–7. http://dx.doi.org/10.1016/j.vaccine.2015.02.008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Campbell, Angela P., Constance Ogokeh, Geoffrey A. Weinberg, Julie A. Boom, Janet A. Englund, John V. Williams, Natasha B. Halasa, et al. "Effect of Vaccination on Preventing Influenza-Associated Hospitalizations Among Children During a Severe Season Associated With B/Victoria Viruses, 2019–2020." Clinical Infectious Diseases 73, no. 4 (January 27, 2021): e947-e954. http://dx.doi.org/10.1093/cid/ciab060.

Повний текст джерела

Анотація:

Abstract Background The 2019–2020 influenza season was characterized by early onset with B/Victoria followed by A(H1N1)pdm09 viruses. Emergence of new B/Victoria viruses raised concerns about possible vaccine mismatch. We estimated vaccine effectiveness (VE) against influenza-associated hospitalizations and emergency department (ED) visits among children in the United States. Methods We assessed VE among children aged 6 months–17 years with acute respiratory illness and ≤10 days of symptoms enrolled at 7 pediatric medical centers in the New Vaccine Surveillance Network. Combined midturbinate/throat swabs were tested for influenza virus using molecular assays. Vaccination history was collected from parental report, state immunization information systems, and/or provider records. We estimated VE from a test-negative design using logistic regression to compare odds of vaccination among children testing positive vs negative for influenza. Results Among 2029 inpatients, 335 (17%) were influenza positive: 37% with influenza B/Victoria alone and 44% with influenza A(H1N1)pdm09 alone. VE was 62% (95% confidence interval [CI], 52%–71%) for influenza-related hospitalizations, 54% (95% CI, 33%–69%) for B/Victoria viruses, and 64% (95% CI, 49%–75%) for A(H1N1)pdm09. Among 2102 ED patients, 671 (32%) were influenza positive: 47% with influenza B/Victoria alone and 42% with influenza A(H1N1)pdm09 alone. VE was 56% (95% CI, 46%–65%) for an influenza-related ED visit, 55% (95% CI, 40%–66%) for B/Victoria viruses, and 53% (95% CI, 37%–65%) for A(H1N1)pdm09. Conclusions Influenza vaccination provided significant protection against laboratory-confirmed influenza-associated hospitalizations and ED visits associated with the 2 predominantly circulating influenza viruses among children, including against the emerging B/Victoria virus subclade.

Стилі APA, Harvard, Vancouver, ISO та ін.

Groothuis, Jessie R., Gordon Meiklejohn, Brian A. Lauer, Myron J. Levin, and Gerard P. Rabalais. "Immunization of High-Risk Infants Younger Than 18 Months of Age with Split-Product Influenza Vaccine." Pediatrics 87, no. 6 (June 1, 1991): 823–28. http://dx.doi.org/10.1542/peds.87.6.823.

Повний текст джерела

Анотація:

Influenza is an important cause of serious illness in very young children with cardiopulmonary disease. A 4-year study was conducted at two centers to assess immunogenicity and safety of influenza split-product vaccine in children aged 3 to 18 months with bronchopulmonary dysplasia and congenital heart disease. A total of 113 children were studied: 62 children 3 to 5 months of age and 51 children 6 to 18 months of age. Sera were drawn prior to first and second immunization and 3 weeks after second immunization and were tested by hemagglutination inhibition; protection was defined as >1:32. Ninety-five children were surveyed for adverse reactions. Seroresponses were age and antigen specific. Best responses for all ages were to A/Mississippi (H3N2) (97%). Children older than 6 months of age had better seroresponses to A/Leningrad (H3N2) (73%, P < .03) and B/Victoria (62%, P < .02) than did children younger than 6 months of age. Seroconversion rates to the remaining anere low. Only 9% of children experienced adverse reactions; all but one were mild. The immunologic mechanisms responsible for preventing serious influenzal disease and more effective immunization strategies need to be defined for very young high-risk children.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ganczak, Maria, Paulina Dubiel, Marzena Drozd-Dąbrowska, Ewelina Hallmann-Szelińska, Karol Szymański, and Lidia B. Brydak. "Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season." International Journal of Environmental Research and Public Health 16, no. 22 (November 14, 2019): 4489. http://dx.doi.org/10.3390/ijerph16224489.

Повний текст джерела

Анотація:

The effects of immunization with subunit inactivated quadrivalent influenza vaccine (QIV) are not generally well assessed in the elderly Polish population. Therefore, this study evaluated vaccine-induced antibody response and its determinants. Methods: Consecutive patients ≥ 55 years old, attending a Primary Care Clinic in Gryfino, Poland, received QIV (A/Michigan/ 45/2015(H1N1)pdm09, A/Singapore/INFIMH-16-0019/2016 (H3N2), B/Colorado/06/2017, B/Phuket/ 3073/2013) between October-December 2018. Hemagglutination inhibition assays measured antibody response to vaccine strains from pre/postvaccination serum samples. Geometric mean titer ratio (GMTR), protection rate (PR) and seroconversion rate (SR) were also calculated. Results: For 108 patients (54.6% males, mean age: 66.7 years) the highest GMTR (61.5-fold) was observed for A/H3N2/, then B/Colorado/06/2017 (10.3-fold), A/H1N1/pdm09 (8.4-fold) and B/Phuket/ 3073/2013 (3.0-fold). Most patients had post-vaccination protection for A/H3N2/ and B/Phuket/3073/ 2013 (64.8% and 70.4%, respectively); lower PRs were observed for A/H1N1/pdm09 (41.8%) and B/Colorado/06/ 2017 (57.4%). The SRs for A/H3N2/, A/H1N1/pdm09, B Victoria and B Yamagata were 64.8%, 38.0%, 46.8%, and 48.2%, respectively. Patients who received QIV vaccination in the previous season presented lower (p < 0.001 and p = 0.03, respectively) response to B Victoria and B Yamagata. Conclusions: QIV was immunogenic against the additional B lineage strain (B Victoria) without significantly compromising the immunogenicity of the other three vaccine strains, therefore, adding a second B lineage strain in QIV could broaden protection against influenza B infection in this age group. As the QIV immunogenicity differed regarding the four antigens, formulation adjustments to increase the antigen concentration of the serotypes that have lower immunogenicity could increase effectiveness. Prior season vaccination was associated with lower antibody response to a new vaccine, although not consistent through the vaccine strains.

Стилі APA, Harvard, Vancouver, ISO та ін.

Svyatchenko, S. V., A. G. Durymanov, I. M. Susloparov, N. P. Kolosova, N. I. Goncharova, O. V. Petrova, A. V. Epanchintseva, et al. "SEVERE CASES OF SEASONAL INFLUENZA IN RUSSIA IN 2015 - 2016 AND 2016 - 2017." Journal of microbiology epidemiology immunobiology, no. 1 (February 28, 2018): 32–39. http://dx.doi.org/10.36233/0372-9311-2018-1-32-39.

Повний текст джерела

Анотація:

Aim. Evaluation of seroprevalence of antibodies to influenza A and В viruses and analysis of specimens from severe or fatal influenza cases in Russia in 2015 - 2016 and 2016 - 2017 flu seasons. Materials and methods. Determination of antibody titer in human serum samples in hemagglutination inhibition assay with reference antigens. Isolation of influenza viruses from nasopharyngeal swabs and autopsy material in cell culture. Characterization ofisolated strains. Results. In 2016, compared to 2015, the proportion of serum samples, containing antibodies to influenza viruses A(H 1N1 pdm09) and A(H3N2), increased. During the 2015-2016 season, elevated number of severe and fatal cases of influenza were registered. The majority of circulated strains belonged to the new clade 6B.1 of A(HlNippdm09 viruses. 1% of analyzed isolates carried H275Y amino acid substitution in neuraminidase and were resistant to oseltamivir. In the 2016 - 2017 season, there were less severe cases of influenza. The most prevalent were influenza viruses A(H3N2) and B/Victoria. Isolated H3N2 viruses belonged to the 3C.2a subclade and B/Victoria isolates were from the 1A genetic group. All tested strains were susceptible to neuraminidase inhibitors. Conclusions. Flu seasons 2015 - 2016 and 2016 - 2017 differed in intensity of influenza activity and in the dominant influenza A virus subtype. Immunization with vaccine, comprising new HlNlpdm09-component, is crucial for prophylaxis of influenza infection with viruses from 6B. 1 subclade in the next season. Neuraminidase inhibitors are recommended for influenza treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Immunization Victoria"

Andrews, Ross. "Pneumococcal vaccine for the elderly : impact of a publicly funded program." Phd thesis, 2004. http://hdl.handle.net/1885/148767.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Immunization Victoria"

Hinman, Alan R., and Walter A. Orenstein. "A Shot at Protection: Immunizations Against Infectious Disease." In Silent Victories, 63–80. Oxford University Press, 2006. http://dx.doi.org/10.1093/acprof:oso/9780195150698.003.04.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ding, Amy Wenxuan. "Weaponizing the Internet and the YouTube War." In Social Computing in Homeland Security, 207–30. IGI Global, 2009. http://dx.doi.org/10.4018/978-1-60566-228-2.ch012.

Повний текст джерела

Анотація:

In the war against terrorist enemies, the United States currently is using a traditional defensive approach: engaging in formal military ground battles with adversaries such as al-Qaeda. By conducting a formal military operation, powerful military forces ideally should defeat terrorists, break up terrorist cells, remove their home bases, disperse leaders, and severely degrade the terrorist groups’ ability to wage attacks against the United States. A traditional military war normally involves two parties with known geographical locations and concentrated battle areas. A victory occurs when an enemy is defeated. However, the war on terrorism represents an opposite situation: without geographic concentration. Modern terrorists operate across national borders and have access to funding and advanced technology with global reach. Terrorists such as al-Qaeda lack geographic homes, which mean the battlefield is geographically dispersed. Furthermore, in addition to using conventional weapons, they increasingly use modern information technology, particularly the Internet, to wage their battles. They ride the back of the Web and use advanced communications to distribute their thoughts or views, gather support, recruit new members, and move immense financial funds from one place to another. According to Weimann (2006), many terrorist groups have their own Web sites on the Internet, which they use to teach their members to prepare computer viruses, worms, Trojan horses, sniffers, and other malicious programs that multiply and cause potentially severe damages. They thus consider the capabilities of the Web as offensive mass weapons that can undermine worldwide actions. The modern Internet penetrates all levels of society, such that information flows continuously and seamlessly across political, ethnic, and religious divides. Because of the global nature of cyberspace, it provides a new platform on which terrorists can wage battles. In this chapter, we examine the role of the Internet as a battlefield and analyze the course of war in cyberspace. We model the Internet structure and determine that the Internet needs a self-immunization mechanism that can self-detect illegal or criminal activities online.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!